With a market cap of $138.2 billion, Pfizer Inc. (PFE) is a leading global biopharmaceutical company headquartered in New ...

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Merck MRK and Pfizer PFE are leading pharmaceutical companies with strong product and pipeline portfolios in oncology. Both companies also have presences in vaccines, neuroscience, and immunology ...

Pfizer is also advancing a robust pipeline of oncology candidates, with several entering late-stage development. By 2030, it expects to have eight or more blockbuster oncology medicines in its ...

Pfizer Inc. continues to showcase potential practice-changing research and next-generation candidates across its robust Oncology portfolio at the European Society for Medical Oncology Congress ...

Key Points: Pfizer's current valuation metrics reveal a striking disconnect with its long-term growth potential The $43 billion Seagen acquisition has fundamentally transformed Pfizer's oncology ...

Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years. Shares are down 19% over ...